Gapping up
In reaction to earnings/guidance:
- ALC +9.9%, INST +7.2%, LOW +4.8%, WB +4.7%, DNUT +2.6%, A +1.7%, LITE +1.7%, TJX +0.8%, TUYA +0.7%
Other news:
- BWAY +21.2% (FDA gives 510(k) clearance for the company's Deep Transcranial Magnetic Stimulation System to treat symptoms of depression)
- TLRY +9.1% (acquires majority position in senior convertible notes of MedMen)
- JKS +6% (signs long-term supply agreement with Wacker Chemie for over 70,000 metric tons of Polysilicon)
- ANAB +5.2% (FDA grants accelerated approval for JEMPERLI)
- STRO +4.4% (FDA grants Fast Track designation for STRO-002 for treatment of ovarian cancer)
- FUV +4% (issues correction, increases the number of manufactured vehicles in Q1 and Q2)
- CABA +3.1% (reports clinical data from the second dose cohort in DesCAARTes trial in patients with mPV)
- TS +2.6% (CEO acquitted by Argentine court in Notebooks Case),
- MRTN +2.5% (declares special cash dividend of $0.50/sh)
- XPEV +2.2% (signs agreement with Zhaoqing Smart EV Manufacturing Base Phase Two expansion project; capacity for Zhaoqing Base to reach 200,000 units)
- REGN +1.9% (Regeneron Pharma and Eli Lilly (LLY) COVID treatments are being used to keep patients out of hospital, according to WSJ)
- VAL +1.4% (awarded one-well contracts with estimated duration of 60 days each)
Analyst comments:
- VIAC +3% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ACVA +2.4% (upgraded to Overweight from Neutral at Piper Sandler)
- BB +1.8% (upgraded to Hold from Sell at Canaccord Genuity)
- SHEN +1.5% (upgraded to Buy from Neutral at B. Riley Securities)